Jyong Biotech Ltd. Ordinary Shares (MENS)

Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.

Jyong Biotech presented Phase III clinical trial results for BOTRESO, a drug for benign prostatic hyperplasia, and Phase II results for MCS-8, a potential prostate cancer prevention drug, at the 22nd Urological Association of Asia Congress.